Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM
2024-511580-28-00Phase 3Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of metformin and colchicine in post-COVID syndrome (4 arms), sponsored by University Medical Center Utrecht. Primary endpoint: PROMIS-29 physical health summary score. Planned start Aug 2024; status: withdrawn.
02
Drugs
metformincolchicine
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2024-511580-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511580-28-00.